CALGARY, Canada – March 6, 2007 – SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical products, today announced the closing of the previously announced over-allotment option whereby Raymond James Inc., on behalf of the syndicate of underwriters, exercised the over-allotment option granted to them in connection with the Company’s previously announced offering of common shares, which closed on February 20, 2007.
